Compile Data Set for Download or QSAR
Report error Found 149 Enz. Inhib. hit(s) with all data for entry = 11711
TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642361BDBM642361(US20230406840, Example 35)
Affinity DataIC50: 0.0970nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642323BDBM642323(US20230406840, Example 3)
Affinity DataIC50: 0.120nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642366BDBM642366(US20230406840, Example 40)
Affinity DataIC50: 0.150nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642372BDBM642372(US20230406840, Example 46)
Affinity DataIC50: 0.180nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642322BDBM642322(US20230406840, Example 2)
Affinity DataIC50: 0.180nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642371BDBM642371(US20230406840, Example 45)
Affinity DataIC50: 0.25nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642350BDBM642350(US20230406840, Example 24)
Affinity DataIC50: 0.300nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642363BDBM642363(US20230406840, Example 37)
Affinity DataIC50: 0.300nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642355BDBM642355(US20230406840, Example 29)
Affinity DataIC50: 0.300nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642349BDBM642349(US20230406840, Example 23)
Affinity DataIC50: 0.330nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642351BDBM642351(US20230406840, Example 25)
Affinity DataIC50: 0.370nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642341BDBM642341(US20230406840, Example 17)
Affinity DataIC50: 0.380nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642333BDBM642333(US20230406840, Example 11)
Affinity DataIC50: 0.400nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642365BDBM642365(US20230406840, Example 39)
Affinity DataIC50: 0.410nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642356BDBM642356(US20230406840, Example 30)
Affinity DataIC50: 0.410nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642321BDBM642321(6-Bromo-N-(2-((1S,3S,5S)-3-cyano-2-azabicyclo[3.1....)
Affinity DataIC50: 0.440nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642346BDBM642346(US20230406840, Example 20)
Affinity DataIC50: 0.480nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642366BDBM642366(US20230406840, Example 40)
Affinity DataIC50: 0.490nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642348BDBM642348(US20230406840, Example 22)
Affinity DataIC50: 0.510nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642369BDBM642369(US20230406840, Example 43)
Affinity DataIC50: 0.560nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642331BDBM642331(US20230406840, Example 9)
Affinity DataIC50: 0.560nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642362BDBM642362(US20230406840, Example 36)
Affinity DataIC50: 0.580nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642361BDBM642361(US20230406840, Example 35)
Affinity DataIC50: 0.640nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642322BDBM642322(US20230406840, Example 2)
Affinity DataIC50: 0.650nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642323BDBM642323(US20230406840, Example 3)
Affinity DataIC50: 0.680nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642352BDBM642352(US20230406840, Example 26)
Affinity DataIC50: 0.700nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642334BDBM642334(US20230406840, Example 12)
Affinity DataIC50: 0.75nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642371BDBM642371(US20230406840, Example 45)
Affinity DataIC50: 0.760nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642338BDBM642338(US20230406840, Example 16)
Affinity DataIC50: 0.810nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642349BDBM642349(US20230406840, Example 23)
Affinity DataIC50: 0.810nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642335BDBM642335(US20230406840, Example 13)
Affinity DataIC50: 0.860nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642336BDBM642336(US20230406840, Example 14)
Affinity DataIC50: 0.910nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642347BDBM642347(US20230406840, Example 21)
Affinity DataIC50: 0.970nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642337BDBM642337(US20230406840, Example 15)
Affinity DataIC50: 1.10nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642370BDBM642370(US20230406840, Example 44)
Affinity DataIC50: 1.10nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642350BDBM642350(US20230406840, Example 24)
Affinity DataIC50: 1.20nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642360BDBM642360(US20230406840, Example 34)
Affinity DataIC50: 1.20nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642354BDBM642354(US20230406840, Example 28)
Affinity DataIC50: 1.30nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 μM FAC (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642364BDBM642364(US20230406840, Example 38)
Affinity DataIC50: 1.30nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642355BDBM642355(US20230406840, Example 29)
Affinity DataIC50: 1.30nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642359BDBM642359(US20230406840, Example 33)
Affinity DataIC50: 1.40nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642348BDBM642348(US20230406840, Example 22)
Affinity DataIC50: 1.5nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642365BDBM642365(US20230406840, Example 39)
Affinity DataIC50: 1.5nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642346BDBM642346(US20230406840, Example 20)
Affinity DataIC50: 1.60nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642341BDBM642341(US20230406840, Example 17)
Affinity DataIC50: 1.70nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642363BDBM642363(US20230406840, Example 37)
Affinity DataIC50: 1.70nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642372BDBM642372(US20230406840, Example 46)
Affinity DataIC50: 1.70nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642351BDBM642351(US20230406840, Example 25)
Affinity DataIC50: 1.80nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642358BDBM642358(US20230406840, Example 32)
Affinity DataIC50: 2nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandChemical structure of BindingDB Monomer ID 642321BDBM642321(6-Bromo-N-(2-((1S,3S,5S)-3-cyano-2-azabicyclo[3.1....)
Affinity DataIC50: 2nMAssay Description:Table 1A: Compounds were tested in a biochemical inhibition assay using hFAP enzyme at 0.24 nM FAC (Proteros, 38-760 (PR-0071)) and the substrate Ala...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
US Patent

Displayed 1 to 50 (of 149 total ) | Next | Last >>
Jump to: